BiotechTube

VTX958 + VTX958 + VTX958 Placebo

Phase 2Terminated
2 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease

Trial Timeline

Jan 25, 2023 → Dec 20, 2024

NCT ID
NCT05688852

About VTX958 + VTX958 + VTX958 Placebo

VTX958 + VTX958 + VTX958 Placebo is a phase 2 stage product being developed by Ventyx Biosciences for Crohn Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05688852. Target conditions include Crohn Disease.

What happened to similar drugs?

12 of 20 similar drugs in Crohn Disease were approved

Approved (12) Terminated (4) Active (8)
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅MirikizumabEli LillyApproved
✅Adalimumab Injection + ThiopurineAbbVieApproved
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05688852Phase 2Terminated

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
42
CT-P13 + RemicadeCelltrionPhase 3
40
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
39
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
33
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CP-461Astellas PharmaPhase 2
35
UstekinumabSun PharmaceuticalPre-clinical
33
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44